• IDEAYA Biosciences recently enrolled the first patient in a Phase 1 trial of IDE892 combined with IDE397 for MTAP-deleted solid tumors and entered a clinical collaboration with Roche, while also naming President and CEO Yujiro S. Hata as Chairman of the Board and appointing Terry Rosen as Lead Independent Director.
• This combination trial and Roche collaboration further concentrate IDEAYA’s precision-oncology efforts on MTAP-deleted cancers, an area with no approved targeted therapies despite substantial patient need.
• We will now examine how the IDE892–IDE397 combination trial, underpinned by synthetic lethality in MTAP-deleted tumors, shapes IDEAYA’s investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is IDEAYA Biosciences' Investment Narrative?

For IDEAYA, the investment case now leans even more on believing in its MTAP-deletion precision-oncology platform alongside the late-stage darovasertib program. The IDE892–IDE397 Phase 1 start and Roche collaboration deepen that MTAP focus, but they are early-stage and unlikely to shift near-term catalysts as much as the anticipated H2 2026 NDA filing for darovasertib plus crizotinib. Instead, they subtly reshape the risk profile: IDEAYA is committing more R&D and scientific identity to MTAP-deleted tumors while remaining unprofitable, with a Q1 2026 net loss of US$98.54 million and no profitability expected in the next three years. Recent board and leadership changes, with Yujiro Hata now also Chairman, concentrate decision making and could matter if trial timelines slip or partner support weakens.

However, one key clinical risk tied to MTAP-deleted programs may surprise some investors. IDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span from about US$52.79 to a very large US$617.80, underlining how far apart individual views can be. Against that backdrop, IDEAYA’s deepening reliance on MTAP-deletion programs and continued losses means your own conviction on clinical execution and cash needs will heavily shape how you interpret those numbers.

Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be worth just $52.79!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 31 stocks that are working to make quantum computing a reality.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.